Navigation Links
Even the boss doesn't follow the doctor's orders
Date:3/2/2010

ANN ARBOR, Mich.---Only 68 percent of corporate executives took their cholesterol lowering medication as prescribed by a doctor, a new study shows.

Overall, the executives who took their medication even sporadically were twice as likely to meet their cholesterol goals. The study finding also questions the prevailing wisdom that income is a primary factor in medication adherence.

University of Michigan researchers studied 1,607 executive level managers at a major financial institution from 1995 to 2004, said Alyssa Schultz, health science research associate at the U-M School of Kinesiology Health Management Research Center, and one of the study authors.

Researchers wanted to discover the rate of medication adherence, and also what happened to cholesterol levels in executives who did or didn't take statins. Statin drugs lower the low-density lipoprotein (LDL) cholesterol, or the so-called bad cholesterol. Statins are proven effective and are a first-line treatment for lowering cholesterol.

Adherence was defined as taking medication as prescribed at least 80 percent of the time. Overall, statin users were twice as likely to meet the near optimal goal of 130 mg/dL or less, than non-statin users. Among executive who took statins, 70 percent achieved the near-optimal goal and 30 percent achieved the optimal goal of 100 mg/dL or less, compared to 55 percent and 21 percent, respectively, for non-statin users who weren't prescribed the drug

Even executives who took their medication sporadically did much better than the non-statin users, Schultz said. "It seems to show that some medication use is better than none, however adherence is associated with the best outcome of all," she said. The executives who actually did adhere to the statin regimen were significantly more likely to achieve their cholesterol goals than those who took the medication sporadically.

Researchers in this study did not look at reasons why the executives did or didn't follow their doctor's orders, but past research on the topic suggests cost is a factor. However, this study population was predominately white male and more highly educated and compensated than more than the average person.

"Many people think cost is the main reason for medication non-adherence but this doesn't appear true since these people have relatively high salaries," said Schultz.

Using statins could actually save money. Previous research on the effectiveness of statin use in a population at high risk for cardiovascular disease found that a health plan with 210,000 covered lives and 9,336 at-risk employees could yield a $1,735 reduction in costs per treated patient.

So what can employers do? Make sure statins are a covered benefit, said Schultz. Do screening to identify at-risk employees. Partner with health care and pharmacy providers to address reasons for poor medication adherence.


'/>"/>

Contact: Laura Bailey
baileylm@umich.edu
734-764-1552
University of Michigan
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
3. Treating depression may improve recovery of heart rate variability following coronary syndromes
4. Study finds primary care depression treatment often does not follow quality guidelines
5. Grocery Shoppers Are Following Stars to More Nutritious Choices
6. PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building
7. Methadone and systematic follow-up: the best solution for managing chronic pain
8. Catheter angiography may be an unnecessary follow-up to CT angiography
9. Conseco to Host Follow-Up Long-Term Care Conference Call
10. EPA Says Follow-Up Sampling Shows No PCB Risk at Park Ridge Elementary School
11. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: a ... “Knowledge is God’s Lighthouse” is the creation of published author, Gene Gaapf, a retired ... collections. , “I have been writing since high school and have many different ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Learning Management System: an On-demand E-learning system for Clinical and Regulatory education ... that is based on Aerolib`s successful education methodology of Disease Specific Documentation ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... January 19, 2017 ... Oncology & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to ... from touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
Breaking Medicine Technology: